UK seeks to use NHS data to drive AI-led pharmaceutical investment

Highlights

UK government plans to leverage decades of NHS health data and a strong AI sector to drive pharmaceutical investment and life sciences growth.
Palantir’s NHS contract will be extended for two years as ministers emphasize UK tech sovereignty in a new procurement process amid ongoing data governance concerns.
Britain's April deal to raise NHS medicine prices for the first time in 25 years brings an estimated £1 billion cost but triggers increased drugmaker investment and approvals.

NHS data strategy and investment push

As reported by the Financial Times, McDonald says the UK has a strategic competitive advantage because it combines decades of longitudinal NHS health data with a sizeable domestic AI sector. Speaking at the FT Global Pharma and Biotech Summit on Wednesday, he says the future of medicines discovery depends on AI and argues that NHS data should become a powerful driver for pharmaceutical investment.

McDonald says the government wants the NHS to play a larger role in supporting life sciences growth as ministers seek to increase pharma investment in the UK. He also insists that the push to commercialise NHS data begun under Sir Keir Starmer continues under Andy Burnham.

He says that ambition depends on maintaining trust in the NHS brand, especially amid concerns over Palantir’s role in the health service and after UK Biobank patient data is offered for sale. Rather than focusing on a single company, McDonald points to governance and assurance, including ministerial pressure on UK Biobank to suspend access after the incident.

Pricing, procurement and sector impact

Palantir’s NHS contract is set to be extended for a further two years while ministers run a new procurement process with greater emphasis on UK tech sovereignty. McDonald says the government can only make fuller use of NHS data for therapeutic gains if it preserves public confidence.

He also links the broader life sciences push to changes in medicine pricing. Under a deal agreed with the U.S. in April, Britain increases NHS prices for new medicines for the first time in 25 years, a move that triggers controversy over an estimated £1 billion cost to the health service over the next three years.

McDonald argues the UK is already seeing more investment from drugmakers as a result, even if the costs and benefits fall unevenly across government. He says the NHS bears the direct cost, while the wider economy and Treasury gain from higher tax revenue, and he points to 10 drugs approved for patients under the new threshold as evidence of early benefit.

The minister does not commit to further price rises sought by the industry, but says the latest changes strengthen his case inside government. He also rejects claims that prioritising AI and life sciences necessarily means cutting other research fields, while blaming reductions affecting projects such as the Diamond Light Source particle accelerator on research administrators.

In a previous article, we explained AstraZeneca’s insitro deal to advance AI-led drug discovery for liver and heart diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.